389,60 €
6,13 % gestern
L&S, 30. Oktober, 22:54 Uhr
ISIN
US02043Q1076
Symbol
ALNY
Berichte

Alnylam Pharmaceuticals, Inc Aktie News

Neutral
Seeking Alpha
etwa 7 Stunden alt
Alnylam Pharmaceuticals, Inc. ( ALNY ) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Christine Lindenboom - Chief Corporate Communications Officer Yvonne Greenstreet - CEO & Director Tolga Tanguler - Executive VP & Chief Commercial Officer Pushkal Garg - EVP of Development & Medical Affairs and Chief Research & Dev. Officer Jeffrey Poulton - CFO & Executive VP Conferen...
Positiv
Investors Business Daily
etwa 14 Stunden alt
Alnylam stock could surge again after the biotech company easily beat Wall Street's third-quarter forecasts on the back of Amvuttra.
Neutral
Business Wire
etwa 14 Stunden alt
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter ended September 30, 2025 and reviewed recent business highlights. “Alnylam's impressive third quarter financial results underscore our ability to consistently deliver innovative medicines to patients aroun...
Positiv
Investors Business Daily
2 Tage alt
Buying a stock is easy, but buying the right stock without a good strategy is incredibly hard. Here are five top-performing stocks to buy now or put on a watchlist.
Positiv
Investors Business Daily
13 Tage alt
S&P 500 giant Walmart and a profitable biotech are actionable, leading five stocks to watch amid a tricky market environment.
Neutral
Business Wire
15 Tage alt
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2025 on Thursday, October 30, 2025, before the U.S. financial markets open. Management will provide an update on the Company and discuss third quarter 2025 results as well as expec...
Neutral
Business Wire
30 Tage alt
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the first patient has been dosed in ZENITH (ZilebEsiraN CardIovascular OuTcome Study in Hypertension), a global Phase 3 cardiovascular outcomes trial (CVOT) designed to evaluate the potential of zilebesiran, an investigational biannual subcutaneously admin...
Neutral
Business Wire
etwa ein Monat alt
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) and the polyneuropathy of hereditary ...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen